Cure of hepatitis C virus infection without interferon alfa: Scientific basis and current clinical evidence

Topics in Antiviral Medicine

Volumn 21, Issue 5, 2014, Pages 152-156

  Thomas, David L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

DAAs; Direct acting antivirals; Genotype; HCV; Hepatitis C; Interferon; Interferon alfa sparing; NS5A; NS5B; Protease inhibitor; Resistance; Simeprevir; Sofosbuvir; Sparing; Treatment

Indexed keywords

ABT 267; ABT 333; ABT 450; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; DELEOBUVIR; FALDAPREVIR; INTERLEUKIN 28B; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ARTICLE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT RESPONSE; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84896696790     PISSN: 21615861     EISSN: 21615853     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315(25):1575-1578.
2. Zeuzem S, Soriano V, Asselah T, et al. Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127 +/-ribavirin (R): final results of the SOUND-C2 and predictors of response [Abstract 232]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 9-13, 2012; Boston, Massachusetts.
3. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013;369(7):630-639.
4. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45-53.
5. Kowdley K, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naive patients and 93% in prior null responders with HCV genotype 1 infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 9-13, 2012; Boston, Massachusetts.
6. Kowdley K, Lawitz E, Poordad F, et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333 +/-ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. 48th Annual Meeting of the European Association for the Study of the Liver. April 24-28, 2013; Amsterdam, The Netherlands.
7. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34-44.
8. Gane E, Stedman C, Anderson J, et al. 100% Rapid virologic response for PSI-7977 + ribavirin in genotype 1 null responders (ELECTRON): early viral decline similar to that observed in genotype 1 and genotype 2/3 treatment-naive patients. 19th Conference on Retroviruses and Opportunistic Infections (CROI). March 5-8, 2012; Seattle, WA.
9. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-1877.
10. Gane E, Hyland R, Ding X, et al. ELECTRON: 100% suppression of viral load through 4 weeks post-treatment for sofosbuvir + ledipasvir (GS-5885) + ribavirin for 12 weeks in treatment-naive and-experienced hepatitis C virus GT1 patients [Abstract 41LB]. 20th Conference on Retroviruses and Opportunistic Infections (CROI). March 3-6, 2013; Atlanta, Georgia.
11. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Suppression of viral load through 4 weeks post-treatment results of a oncedaily regimen of simeprevir + sofosbuvir with or without ribavirin in hepatitis C virus GT1 null responders [Abstract 155LB]. 20th Conference on Retroviruses and Opportunistic Infections (CROI). March 3-6, 2013; Atlanta, Georgia.
12. Sulkowski M, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). 20th Conference on Retroviruses and Opportunistic Infections (CROI). April 24-28, 2013; Amsterdam, The Netherlands.